-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Myasthenia gravis (MG) is the most common autoimmune disease affecting the neuromuscular junction and is characterized by antibody (ab)-mediated dysfunction of the postsynaptic membrane
Therefore, eculizumab, a humanized monoclonal antibody ablated with eculizumab in a phase 3 randomized placebo-controlled trial, has been shown to be refractory to treatment of anti-AChR antibody-positive (TR ) MG patients are effective
Two biopharmaceuticals, rituximab and ecuadorizumab, can both be considered as treatment options for refractory MG after failure of immunosuppressive standard therapies (ISTs)
The cohort was performed on patients from six university hospitals (University Hospital Berlin, University Hospital Cologne, University Hospital Düsseldorf, University Hospital Freiburg, University Hospital Magdeburg and University Hospital Regensburg) Retrospective, observational multicenter analysis
The cohort was performed on patients from six university hospitals (University Hospital Berlin, University Hospital Cologne, University Hospital Düsseldorf, University Hospital Freiburg, University Hospital Magdeburg and University Hospital Regensburg) Retrospective, observational multicenter analysis
The two groups were comparable in terms of clinical and demographic characteristics .
The efficacy of rituximab and ecuadorizumab in the treatment of refractory and systemic anti-AChR antibody-positive MG was
Time to MG phenomenon after baseline examination
At 12 and 24 months of treatment, ecuuzumab-treated patients were also more likely to develop MM than rituximab-treated patients, and the risk of MC was comparable between the two groups
The current sample size of patients treated with ecuuzumab may not detect the effect on MC, and prospective trials are needed to better understand the long-term efficacy of ecuuzumab compared to established treatment strategies
NelkeC ,SchroeterCB ,StascheitF NelkeCNelke SchroeterCBSchroeter Stascheit FStascheit, et alEculizumab versus rituximab in generalised myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry Published Online First: 04 March 2022.
Published Online First: doi: 10.
1136/ jnnp-2021-328665doi:
leave a message here
